Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine.

Maeda T, Hosen N, Fukushima K, Tsuboi A, Morimoto S, Matsui T, Sata H, Fujita J, Hasegawa K, Nishida S, Nakata J, Nakae Y, Takashima S, Nakajima H, Fujiki F, Tatsumi N, Kondo T, Hino M, Oji Y, Oka Y, Kanakura Y, Kumanogoh A, Sugiyama H.

Blood Cancer J. 2013 Aug 2;3:e130. doi: 10.1038/bcj.2013.29. No abstract available.

2.

The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.

Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M, Creutzig U, Klingebiel T.

Haematologica. 2012 Jan;97(1):21-9. doi: 10.3324/haematol.2011.051714. Epub 2011 Sep 20.

3.

Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research.

Keating A, DaSilva G, Pérez WS, Gupta V, Cutler CS, Ballen KK, Cairo MS, Camitta BM, Champlin RE, Gajewski JL, Lazarus HM, Lill M, Marks DI, Nabhan C, Schiller GJ, Socie G, Szer J, Tallman MS, Weisdorf DJ.

Haematologica. 2013 Feb;98(2):185-92. doi: 10.3324/haematol.2012.062059. Epub 2012 Sep 14.

4.

Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.

Pfeiffer T, Schleuning M, Mayer J, Haude KH, Tischer J, Buchholz S, Bunjes D, Bug G, Holler E, Meyer RG, Greinix H, Scheid C, Christopeit M, Schnittger S, Braess J, Schlimok G, Spiekermann K, Ganser A, Kolb HJ, Schmid C.

Haematologica. 2013 Apr;98(4):518-25. doi: 10.3324/haematol.2012.070235. Epub 2012 Sep 14.

5.

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.

Stelljes M, Beelen DW, Braess J, Sauerland MC, Heinecke A, Berning B, Kolb HJ, Holler E, Schwerdtfeger R, Arnold R, Spiekermann K, Müller-Tidow C, Serve HL, Silling G, Hiddemann W, Berdel WE, Büchner T, Kienast J; German AML Cooperative Group (AMLCG).

Haematologica. 2011 Jul;96(7):972-9. doi: 10.3324/haematol.2011.041004. Epub 2011 Apr 1.

6.

Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.

Kwon M, Martínez-Laperche C, Infante M, Carretero F, Balsalobre P, Serrano D, Gayoso J, Pérez-Corral A, Anguita J, Díez-Martín JL, Buño I.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1235-42. doi: 10.1016/j.bbmt.2012.01.012. Epub 2012 Jan 25.

7.

The role of allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.

Paulson K, Szwajcer D, Seftel MD.

Transfus Apher Sci. 2011 Apr;44(2):197-203. doi: 10.1016/j.transci.2011.01.016. Epub 2011 Feb 16. Review.

PMID:
21330213
8.

[Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].

Sun J, Meng FY, Liu QF, Xu D, Xu B, Liu XL.

Ai Zheng. 2003 Dec;22(12):1321-4. Chinese.

PMID:
14693060
9.

Autologous stem cell transplantation versus alternative allogeneic donor transplants in adult acute leukemias.

Claude Gorin N.

Semin Hematol. 2016 Apr;53(2):103-10. doi: 10.1053/j.seminhematol.2016.01.003. Epub 2016 Jan 19. Review.

PMID:
27000734
10.
11.

Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.

Simon W, Segel GB, Lichtman MA.

Blood Cells Mol Dis. 2006 Sep-Oct;37(2):116-24; discussion 125-7. Epub 2006 Aug 10.

PMID:
16904348
12.

Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.

Shin HJ, Kim HJ, Sohn SK, Min YH, Won JH, Kim I, Yoon HJ, Lee JH, Jo DY, Joo YD, Jung CW, Lee KH; Korean Society of Hematology, AML/MDS Working Party, Chung JS, Ahn JS, Kim SJ, Lee JH, Choi SJ, Lee JH, Bae SH, Hong DS, Zang DY, Kim SH, Lee JL, Bang SM.

Jpn J Clin Oncol. 2010 Jun;40(6):556-66. doi: 10.1093/jjco/hyq007. Epub 2010 Feb 25.

PMID:
20185460
13.

Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, Kuball J, Chevallier P, Craddock C, Socie G, Bilger K, Schouten HC, Fegueux N, Goker H, Maertens J, Bunjes D, Arnold R, Nagler A, Mohty M.

Cancer. 2014 Mar 15;120(6):855-63. doi: 10.1002/cncr.28498. Epub 2013 Dec 10.

14.

Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.

Rossi G, Carella AM, Minervini MM, Savino L, Fontana A, Pellegrini F, Greco MM, Merla E, Quarta G, Loseto G, Capalbo S, Palumbo G, Cascavilla N.

Leuk Lymphoma. 2013 Dec;54(12):2660-6. doi: 10.3109/10428194.2013.789508. Epub 2013 May 15.

PMID:
23547840
16.

Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.

Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández-Rivas JM, Moreno MJ, del Potro E, Torm M, Rivas C, Besalduch J, Sanz MA, Ortega JJ; PETHEMA Group, Spain.

Haematologica. 2005 Oct;90(10):1346-56.

17.

Hematopoietic stem cell transplantation in acute promyelocytic leukemia, experience in Iran.

Alimoghaddam K, Ghavamzadeh A, Jahani M, Jalali A, Jorjani H, Iravani M, Hamidieh AA, Mousavi A, Bahar B, Behfar M, Derakhshandeh R, Rostami S.

Arch Iran Med. 2011 Sep;14(5):332-4. doi: 008.

18.

Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation.

Farina L, Carniti C, Dodero A, Vendramin A, Raganato A, Spina F, Patriarca F, Narni F, Benedetti F, Olivieri A, Corradini P.

Haematologica. 2009 May;94(5):654-62. doi: 10.3324/haematol.2008.000273. Epub 2009 Apr 18.

19.
20.

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.

Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H, Usuki K, Yamashita T, Okoshi Y, Shibayama H, Nakamae H, Mawatari M, Hatanaka K, Sunami K, Shimoyama M, Fujishima N, Maeda Y, Miura I, Takaue Y, Fukuda T.

Haematologica. 2010 Nov;95(11):1857-64. doi: 10.3324/haematol.2010.027516. Epub 2010 Jul 15.

Supplemental Content

Support Center